Skip to main content

Table 3 Primary diagnosis and prevalence of causative Candida species

From: Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B

Characteristic Micafungin Liposomal amphotericin B Total
  Non-ICU (n = 127) ICU (n = 120) Non-ICU (n = 136) ICU (n = 110) Non-ICU (n = 263) ICU (n = 230)
Primary diagnosis       
   Candidemia 109 (85.8) 98 (81.7) 115 (84.6) 94 (85.5) 224 (85.2) 192 (83.5)
   Invasive candidiasis 18 (14.2) 22 (18.3) 21 (15.4) 16 (14.5) 39 (14.8) 38 (16.5)
Isolated Candida spp. at baselinea
   Candida albicans 44 (34.6) 58 (48.3) 55 (40.4) 54 (49.1) 99 (37.6) 112 (48.7)
   Candida parapsilosis 29 (22.8) 13 (10.8) 22 (16.2) 16 (14.5) 51 (19.4) 29 (12.6)
   Candida tropicalis 37 (29.1) 29 (24.2) 36 (26.5) 26 (23.6) 73 (27.8) 55 (23.9)
   Candida glabrata 15 (11.8) 15 (12.5) 10 (7.4) 9 (8.2) 25 (9.5) 24 (10.4)
   Candida krusei 5 (3.9) 4 (3.3) 9 (6.6) 1 (0.9) 14 (5.3) 5 (2.2)
   Other Candida species 6 (4.7) 11 (9.2) 17 (12.5) 14 (12.7) 23 (8.7) 25 (10.9)
  1. Data presented as n (%). ICU, intensive care unit. aA patient may have had more than one Candida spp. isolated at baseline.